Regnum (RGMP) Stock Price

Regnum Price

OTC·CLOSED
0.00
​
Market closed

Revenue at Regnum has contracted by 20.6% per year over the past 3 years to 10,000.00 USD. Regnum's net margin stands at -1,200.0%, down from 0.0% several years earlier.

Regnum stock price

Access this data via the Eulerpool API

Regnum business model & stock analysis

Regnum Corp. engages in the business of developing and commercializing therapeutics that treat rare and infectious diseases. The company is headquartered in New York City, New York. The company went IPO on 2019-03-15. The firm's primary asset is the commercial rights to leronlimab (PRO 140) in all human immunodeficiency virus (HIV) indications within the United States. Leronlimab is a monoclonal antibody. The target of leronlimab is the immunologic receptor CCR5. Leronlimab prevents certain strains of HIV from using the CCR5 receptor as an entry gateway for healthy cells. The leronlimab antibody belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells. Leronlimab blocks HIV from entering a cell by binding to a molecule called CCR5 referred to as R5 strains, attach as part of HIVs entry into a cell.

Frequently asked questions about Regnum

Converted at the current exchange rate, the Regnum share trades at 0.00 EUR (0.00 USD).

The revenue cannot currently be calculated for Regnum.

The profit cannot currently be calculated for Regnum.

The P/E ratio cannot be calculated for Regnum at the moment.

The P/S cannot be calculated for Regnum currently.

The Eulerpool Quality Score for Regnum is 2/10.

The ISIN of Regnum is US75915R1068. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Regnum is RGMP. The ticker symbol is used to trade Regnum shares on the stock exchange.

Fair ValueTerminal
0.00 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
—
Industry
Other
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Mar 15, 2019
ISIN
US75915R1068
Cusip
75915R106
Market capitalization
2,295.00 USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
0.23
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-195.00 %
Last updated Oct 11, 2026, 3:41 AM

Regnum Peer Group

Regnum Ticker

OTC · RGMPOTC · RGMP

Regnum FIGI

RGMP:US · BBG00JQ51VL5RGMP:PQ · BBG00KGGSKW2RGMP:UV · BBG00KGGSKX1

All fundamentals and in-depth analysis of Regnum

Our stock analysis for Regnum stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Regnum. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.